Though CVS Health and Aetna have had a working relationship since 2010, and their pending merger had likely been in the works for some time, its timing, experts say, suggests that the merger is as much about staving off the looming threat from Amazon as it is about competing with top health insurers and retailers.
Diplomat Pharmacy has announced that co-founder, CEO and chairman Phil Hagerman is retiring. The Flint, Mich.-based company has named board member Jeff Park as interim CEO, effective immediately. Hagerman will continue as a member of the board and become chairman emeritus, with Ben Wolin taking over as chairman, effective immediately.
Needle-free injection technology company PharmaJet, based in Golden, Colo., will be working with French biopharma company Invectys to test Invectys' therapeutic cancer vaccine. The Phase 2 trial is for INVAC-1, which uses PharmaJet’s needle-free injection system and is an immunotherapeutic DNA vaccine meant to treat cancer, the companies said.
It has been announced by the United States subsidiary of Dr.Reddy’s Laboratories, that the company has reached a settlement with the U.S. Government in a case involving packaging for five blister-packed prescription products.
In a joint filing, both parties have agreed to a settlement of the action without any adjudication or issue of fact or law. The matter has been settled for $5 million dollars, and the product in question has not been distributed in the packaging at issue since June 2012, the company said.
The Food and Drug Administration recently approved Pfizer’s Ixifi (infliximab-qbtx), the company’s second approved biosimilar of Janssen’s Remicade. The biosimilar was approved for all of Remicade’s indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis, among others.
The approval follows the April 2016 launch of its first Remicade biosimilar Inflectra. According to reports, Pfizer has said it has no plans to launch Ixifi in the United States.
The Food and Drug Administration has given full approval to Sanofi’s Admelog short-acting insulin lispro — a follow-on of Eli Lilly’s Humalog. The product received tentative approval from the FDA earlier this year, and now it is the first short-acting follow-on product to get the FDA’s stamp of approval.